Journal of the Neurological Sciences
Volume 217, Issue 1 , Pages 25-30 , 15 January 2004

Effects of antineuronal antibodies from patients with paraneoplastic neurological syndrome on primary-cultured neurons

  • Keiko Tanaka

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +81-25-227-0664; fax: +81-25-223-6646.
    • Department of Neurology, Brain Research Institute, Niigata University, 1-757 Asahimachi-dori, Niigata 951-8585, Japan
    • ,
  • Xin Ding

      Affiliations

    • Department of Neurology, Brain Research Institute, Niigata University, 1-757 Asahimachi-dori, Niigata 951-8585, Japan
    • ,
  • Masami Tanaka

      Affiliations

    • Department of Neurology, National Nishi-Niigata Central Hospital, Niigata, Japan

Received 14 May 2003 ,Revised 4 August 2003 ,Accepted 5 August 2003.

References 

  1. Posner JB. Paraneoplastic syndromes. In: Neurological complications of cancer. Philadelphia: FA Davis; 1995;p. 353–385
  2. Dropcho EJ. Neurologic paraneoplastic syndromes. J. Neurol. Sci. 1998;153:264–278
  3. Lang B, Newsom-Davis J, Wray D, Vincent A. Autoimmune aetiology for myasthenic (Eaton–Lambert) syndrome. Lancet. 1981;ii:224–226
  4. Adamus G, Machnicki M, Seigel GM. Apoptotic retinal cell death induced by antirecoverin autoantibodies of cancer-associated retinopathy. Invest. Ophthalmol. Vis. Sci. 1997;38:283–291
  5. Sillevis SP, Kinoshita A, DeLeeuw B, et al.  Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N. Engl. J. Med. 2000;342:21–27
  6. Greenlee JE, Parks TN, Jaeckle KA. Type IIa (“anti-Hu”) antineuronal antibodies produce destruction of rat cerebellar granule neurons in vitro. Neurology. 1993;43:2049–2054
  7. Sillevis-Smitt PA, Manley GT, Posner JB. Immunization with the paraneoplastic encephalomyelitis antigen HuD dose not cause neurologic disease in mice. Neurology. 1995;45:1873–1878
  8. Tanaka K, Tanaka M, Onodera O, Igarashi S, Miyatake T, Tsuji S. Passive transfer and active immunization with the recombinant leucine-zipper (Yo) protein as an attempt to establish an animal model of paraneoplastic cerebellar degeneration. J. Neurol. Sci. 1994;127:153–158
  9. Tanaka M, Tanaka K, Onodera O, Tsuji S. Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody: I. Mouse strains bearing different MHC molecules produce antibodies on immunization with recombinant Yo protein, but do not cause Purkinje cell loss. Clin. Neurol. Neurosurg. 1995;97:95–100
  10. Graus F, Illa A, Agusti M, et al.  Effect of intraventricular injection of an anti-Purkinje cell antibody (anti-Yo) in a guinea pig model. J. Neurol. Sci. 1991;106:82–87
  11. Rosenblum MK. Paraneoplasia and autoimmunologic injury of the nervous system: the anti-Hu syndrome. Brain Pathol. 1993;3:199–212
  12. Graus F, Ribalta T, Campo E, Monforte R, Urbano A, Rozman C. Immunohistochemical analysis of the immune reaction in the nervous system in paraneoplastic encephalomyelitis. Neurology. 1990;40:219–222
  13. Jean WC, Dalmau J, Ho A, Posner JB. Analysis of the IgG subclass distribution and inflammatory infiltrates in patients with anti-Hu-associated paraneoplastic encephalomyelitis. Neurology. 1994;44:140–147
  14. Vershuuren J, Chuang L, Rosenblum MK, Lieberman F, Pryor A, Posner JB, et al.  Inflammatory infiltrates and complete absence of Purkinje cells in anti-Yo-associated paraneoplastic cerebellar degeneration. Acta Neuropathol. 1996;91:519–525
  15. Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration: I. A clinical analysis of 55 anti-Yo antibody positive patients. Neurology. 1992;42:1931–1937
  16. Tanaka M, Tanaka K, Shinozawa K, Idezuka J, Tsuji S. Cytotoxic T cells react with recombinant Yo protein from a patient with paraneoplastic cerebellar degeneration and anti-Yo antibody. J. Neurol. Sci. 1998;161:88–90
  17. Tanaka K, Tanaka M, Inuzuka T, Nakano R, Tsuji S. Cytotoxic T lymphocyte-mediated cell death in paraneoplastic sensory neuronopathy with anti-Hu antibody. J. Neurol. Sci. 1999;163:159–162
  18. Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaf N, Darnell RB. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat. Med. 1998;4:1321–1324
  19. Tanaka K, Tanaka M, Onodera O, Igarashi S, Tsuji S. The detection of anti-Purkinje cell antibody (anti-Yo antibody) by ELISA using recombinant Yo fusion protein. Brain Nerve. 1994;46:47–51
  20. Yagi Y, Inuzuka T, Takada K, Nakano R, Hozumi I, Yoshimoto H, et al.  Changes in anti-HuD antibody titers in the long-term course in paraneoplastic sensory neuropathy. Eur. J. Neurol. 1997;37:122–123
  21. Tanaka M, Tanaka K, Tokiguchi S, Shinozawa K, Ysuji S. Cytotoxic T cells against a peptide of Yo protein in patients with paraneoplastic cerebellar degeneration and anti-Yo antibody. J. Neurol. Sci. 1999;168:28–31
  22. Tanaka M, Tanaka K, Tsuji S. Cytotoxic T cells react with peptide (S) other than nonapeptide AYRARALEL in paraneoplastic cerebellar degeneration with anti-Yo antibody. Biomed. Res. 1999;20:123–125
  23. Tanaka M, Tanaka K, Miyamoto N, Kamakura K. A peptide with the binding motif for the HLA B7 supertype reacts with CD8-positive cytotoxic T cells in anti-Hu syndrome. Biomed. Res. 2000;21:25–29
  24. Tanaka M, Tanaka K, Tsuji S, Kawata A, Kojima S, Kurokawa T, et al.  Cytotoxic T cell activity against the peptide, AYRARALEL, from Yo protein of patients with the HLA A24 or B27 supertype and paraneoplastic cerebellar degeneration. J. Neurol. Sci. 2001;188:61–65
  25. Tanaka M, Maruyama Y, Sugie M, Motizuki H, Kamakura K, Tanaka K. Cytotoxic T cell activity against peptides of Hu protein in anti-Hu syndrome. J. Neurol. Sci. 2002;201:9–12
  26. Hida C, Tsukamoto T, Awano H, Yamamoto T. Ultrastructural localization of anti-Purkinje cell antibody-binding sites in paraneoplastic cerebellar degeneration. Arch. Neurol. 1994;51:555–558
  27. Fathallah-Shaykh H, Wolf S, Wong E, Posner BJ, Furneaux HM. Cloning of a leucine-zipper protein recognized by the sera of patients with antibody-associated paraneoplastic cerebellar degeneration. Proc. Natl. Acad. Sci. U. S. A. 1991;88:3451–3454
  28. Sakai K, Ogasawara T, Hirose G, Jaeckle KA, Greenlee JE. Analysis of autoantibody binding to 52-kd paraneoplastic cerebellar degeneration-associated antigen expressed in recombinant proteins. Ann. Neurol. 1993;33:373–380
  29. Takanaga H, Mukai H, Shibata H, Toshimori M, Ono Y. PKN interacts with a paraneoplastic cerebellar degeneration-associated antigen, which is a potential transcription factor. Exp. Cell Res. 1998;241:363–372
  30. Okano HJ, Darnell RB. A hierarchy of Hu RNA binding proteins in developing and adult neurons. J. Neurosci. 1997;17:3024–3037
  31. Szabo A, Dalmau J, Manley G, Rosenfeld M, Wong E, Henson J, et al.  HuD, a paraneoplastic encephalomyelitis antigen, contains RNA-binding domains and is homologous to Elav and Sex-lethal. Cell. 1991;67:325–333
  32. Levine TD, Gao F, King PH, Andrews LG, Keene JD. Hel-N1: an autoimmune RNA-binding protein with specificity for 3′ uridylate-rich untranslated regions of growth factor mRNAs. Mol. Cell Biol. 1993;13:3494–3504
  33. Antic D, Lu N, Keene JD. ELAV tumor antigen, Hel-N1, increases translation of neurofilament M mRNA and induces formation of neuritis in human teratocarcinoma cells. Genes Dev. 1999;13:449–461
  34. Chung S, Eckrich M, Perrone-Bizzozero N, et al.  The Elav-like proteins bind to a conserved regulatory element in the 3′-untranslated region of GAP-43 mRNA. J. Biol. Chem. 1997;272:6593–6598
  35. Aranda-Abreu GE, Behar L, Chung S, Furneaux H, Ginzburg I. Embryonic lethal abnormal vision-like RNA-binding proteins regulate neurite outgrowth and tau expression in PC12 cells. J. Neurosci. 1999;19:6907–6917
  36. Joseph B, Orlian M, Furneaux H. p21 (waf1) mRNA contains a conserved element in its 3′-untranslated region that is bound by the Elav-like mRNA-stabilizing proteins. J. Biol. Chem. 1998;273:20511–20516
  37. Kumagai T, Sakai K, Kitagawa Y, Hirose G. Antibody recognition and RNA binding of a neuronal nuclear autoantigen associated with paraneoplastic neurological syndromes and small cell lung carcinoma. J. Neuroimmunol. 1999;93:37–44

PII: S0022-510X(03)00238-7

doi: 10.1016/j.jns.2003.08.006

Journal of the Neurological Sciences
Volume 217, Issue 1 , Pages 25-30 , 15 January 2004

Article Tools

* Image Usage & Resolution